These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22983924)

  • 1. Short-term topiramate treatment does not improve insulin sensitivity or secretion in obese insulin-resistant women.
    Sleddering MA; Snel M; Streefland TC; Pijl H; Jazet IM
    Eur J Endocrinol; 2012 Dec; 167(6):839-45. PubMed ID: 22983924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
    Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M;
    Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
    Rosenstock J; Hollander P; Gadde KM; Sun X; Strauss R; Leung A;
    Diabetes Care; 2007 Jun; 30(6):1480-6. PubMed ID: 17363756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 6 months supplementation with conjugated linoleic acid on insulin resistance in overweight and obese.
    Syvertsen C; Halse J; Høivik HO; Gaullier JM; Nurminiemi M; Kristiansen K; Einerhand A; O'Shea M; Gudmundsen O
    Int J Obes (Lond); 2007 Jul; 31(7):1148-54. PubMed ID: 17031391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension.
    Tonstad S; Tykarski A; Weissgarten J; Ivleva A; Levy B; Kumar A; Fitchet M
    Am J Cardiol; 2005 Jul; 96(2):243-51. PubMed ID: 16018851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
    Bray GA; Hollander P; Klein S; Kushner R; Levy B; Fitchet M; Perry BH
    Obes Res; 2003 Jun; 11(6):722-33. PubMed ID: 12805393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes.
    Stenlöf K; Rössner S; Vercruysse F; Kumar A; Fitchet M; Sjöström L;
    Diabetes Obes Metab; 2007 May; 9(3):360-8. PubMed ID: 17391164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.
    Astrup A; Caterson I; Zelissen P; Guy-Grand B; Carruba M; Levy B; Sun X; Fitchet M
    Obes Res; 2004 Oct; 12(10):1658-69. PubMed ID: 15536230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
    Tremblay A; Chaput JP; Bérubé-Parent S; Prud'homme D; Leblanc C; Alméras N; Després JP
    Eur J Clin Pharmacol; 2007 Feb; 63(2):123-34. PubMed ID: 17200837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fat mass largely contributes to insulin mediated glucose uptake in morbidly obese subjects.
    Gniuli D; Castagneto-Gissey G; Iaconelli A; Leccesi L; Mingrone G
    Int J Obes (Lond); 2010 Dec; 34(12):1726-32. PubMed ID: 20498658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
    Arslanian SA; Lewy V; Danadian K; Saad R
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
    Shankar SS; Shankar RR; Mixson LA; Miller DL; Pramanik B; O'Dowd AK; Williams DM; Frederick CB; Beals CR; Stoch SA; Steinberg HO; Kelley DE
    Diabetes; 2018 Jun; 67(6):1105-1112. PubMed ID: 29545266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study.
    McElroy SL; Hudson JI; Capece JA; Beyers K; Fisher AC; Rosenthal NR;
    Biol Psychiatry; 2007 May; 61(9):1039-48. PubMed ID: 17258690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals.
    Potter van Loon BJ; Radder JK; Frölich M; Krans HM; Zwinderman AH; Meinders AE
    Int J Obes Relat Metab Disord; 1992 Feb; 16(2):79-85. PubMed ID: 1316330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine.
    Abo-Elmatty DM; Zaitone SA
    Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1187-95. PubMed ID: 22165681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance in obesity can be reliably identified from fasting plasma insulin.
    ter Horst KW; Gilijamse PW; Koopman KE; de Weijer BA; Brands M; Kootte RS; Romijn JA; Ackermans MT; Nieuwdorp M; Soeters MR; Serlie MJ
    Int J Obes (Lond); 2015 Dec; 39(12):1703-9. PubMed ID: 26155920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome.
    Lewy VD; Danadian K; Witchel SF; Arslanian S
    J Pediatr; 2001 Jan; 138(1):38-44. PubMed ID: 11148510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes.
    Luzio SD; Dunseath G; Owens DR
    Horm Metab Res; 2002 May; 34(5):271-4. PubMed ID: 12063642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.